Which radiation dose is best for prostate cancer? new trial aims to find out
NCT ID NCT03827616
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial compares two common radiotherapy schedules for prostate cancer: 70 Gy in 28 sessions versus 60 Gy in 20 sessions. Both are already used in clinics, but it is not clear which one works better or causes fewer side effects. The study involves 400 men with early-stage prostate cancer and will track cancer recurrence over 5 to 10 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radiation therapy (hypofractionated intensity-modulated radiotherapy using helical tomotherapy)
What this could lead to
If this trial succeeds, it could help doctors choose the best radiotherapy schedule for prostate cancer, improving cancer control and reducing side effects.
What could go wrong
This is a phase 2 trial, so results are not definitive. Both schedules are already standard, so the difference may be small, and long-term outcomes are still being tracked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tatarstan Cancer Cente
Kazan', Tatarstan Republic, 420029, Russia